2018年8月2日星期四

Ipamorelin--Safest Bodybuilding Peptides

Function of Ipamorelin is similar to GHRP-6 in the way of increasing ghrelin and gastricmotility, and targeting a selective GH pulse. Differ from GHRP-2 and GHRP-6, Ipamorelin cause no hunger side effect, which makes it a versatile peptide for before-bed time dosing.
There is almost no direct impact on cortisol or prolactin production was shown when we're at high dose Ipamorelin. In this case, users can dose higher and with greater frequency without having to be worried about cortisol and acetylcholine blood plasma levels being elevated.
In short, it may be the mildest GHRP, but it is not the weakest. As a GHRP, it has shown to be one of longest lasting, and at higher doses, the most potent. Ipamorelin’s function is a slow building one that is much more like the body’s natural growth hormone (GH) release. This makes it the healthiest choice.


Sides Effects

Among the GHRP family, although Ipamorelin is the mildest and safest peptides, it still comes with side effects. Most users will find the common side effect of a head rush-like feeling and slight headaches. It is suggested that users start supplementation at a lower dose and work their way up. In addition, it is best to inject Ipamorelin 30-45 minutes before working out so that the user is getting the double benefit of both growth hormones working together to maximize results.


Dosage and Usage

Ipamorelin is also comes as a freeze dried powder like other peptides, which is very fragile. It's better to be stored in the refrigerator or at room temperature before reconstituting. Once reconstituted with bacteriostatic water, the vials must be stored in a cool dry place like your refrigerator. Insulin syringes are the best way to administer it, usually via subcutaneous injection.
Using Ipamorelin with a GHRH like CJC w/out DAC will give the users the biggest increase in GH and IGF-1 as GHRP’s and GHRH’s work together synergetically. The average dosing for Ipamorelin is 200-300mcg two to three times daily.

没有评论:

发表评论